进展期IBD治疗改善肠道急迫感的荟萃分析
结果显示,与安慰剂相比,所有诱导治疗(RR 1.77,95%CI 1.51-2.08)和维持治疗(RR 2.40,95%CI 1.54-3.73)均显著提高BU缓解可能性,且抗IL-23药物与JAK抑制剂之间无重大差异。
要点
- 进展期IBD治疗可快速且持续改善肠道急迫感
- 诱导和维持治疗均显著优于安慰剂
- 不同机制药物对BU改善程度相似
核心结论
- 不同作用机制的进展期IBD治疗均能快速且持续改善肠道急迫感
- 各药物间BU改善程度相似
研究设计与样本
- 纳入29项RCT和15项RCT事后研究,代表八种治疗药物
- 仅纳入以二分变量定量报告BU缺失的研究进行荟萃分析
- 按IBD亚型进行亚组分析
- 报告风险比(RR)及95%置信区间(CI)
主要发现
- 所有诱导治疗对比安慰剂显著提高BU缓解可能性(RR 1.77,95%CI 1.51-2.08)
- 所有维持治疗对比安慰剂显著提高BU缓解可能性(RR 2.40,95%CI 1.54-3.73)
- 抗IL-23药物(risankizumab、mirikizumab、guselkumab)与JAK抑制剂upadacitinib之间无重大差异
临床怎么用
- 进展期IBD治疗选择时可考虑其对BU的改善作用
- 不同机制药物对BU改善程度相似,选择时可综合其他因素
局限性
- 仅纳入报告BU缺失为二分变量的研究
- BU常被临床试验低估报告
- 需未来研究其他IBD治疗对BU的影响及标准化测量
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory bowel diseases (IBD) are chronic conditions that significantly affect quality of life. Bowel urgency, a particularly disruptive symptom of IBD, is often underreported in clinical trials. AIMS: To examine the effects of IBD therapies on bowel urgency (BU), focusing on the degree and durability of improvement. METHODS: We searched MEDLINE, Embase, and Cochrane databases in December 2024 for studies that reported a BU outcome for IBD therapies. We included only those studies that reported the absence of BU as a quantitative, binary outcome in the meta-analysis. We also performed a subgroup analysis by IBD subtype. We report risk ratios (RR) with 95% confidence intervals (CI). RESULTS: We included 29 randomised controlled trials (RCTs) and 15 post hoc studies of RCTs representing eight therapeutic agents. There was significantly improved likelihood of BU remission across all induction (RR 1.77, CI 1.51-2.08) and maintenance (RR 2.40, CI 1.54-3.73) therapies compared to placebo, and no major differences between anti-interleukin-23 agents (risankizumab, mirikizumab, guselkumab) and a JAK-inhibitor (upadacitinib). CONCLUSIONS: Advanced IBD therapies with different mechanisms of action produce rapid and sustained improvement in BU. The degree of BU improvement was similar among agents. Areas for future research include investigation of BU outcomes with other IBD therapies, exploration of underlying mechanisms of action, and greater standardisation for measuring BU through validated scores.
引用
- Patel P, Belesiotis P, Rai NS, et al. Meta-Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2025. PMID: 41185967. doi:10.1111/apt.70446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。